Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Long-Term Investments (2018 - 2025)

Historic Long-Term Investments for Catalyst Pharmaceuticals (CPRX) over the last 5 years, with Q3 2025 value amounting to $19.2 million.

  • Catalyst Pharmaceuticals' Long-Term Investments rose 2914.03% to $19.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.2 million, marking a year-over-year increase of 2914.03%. This contributed to the annual value of $21.6 million for FY2024, which is 3077.81% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Long-Term Investments is $19.2 million, which was up 2914.03% from $21.3 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Long-Term Investments' 5-year high stood at $24.2 million during Q1 2025, with a 5-year trough of $12.9 million in Q3 2023.
  • For the 3-year period, Catalyst Pharmaceuticals' Long-Term Investments averaged around $17.7 million, with its median value being $16.5 million (2023).
  • In the last 5 years, Catalyst Pharmaceuticals' Long-Term Investments surged by 1508.1% in 2024 and then skyrocketed by 6247.04% in 2025.
  • Catalyst Pharmaceuticals' Long-Term Investments (Quarter) stood at $16.5 million in 2023, then surged by 30.78% to $21.6 million in 2024, then fell by 11.12% to $19.2 million in 2025.
  • Its Long-Term Investments was $19.2 million in Q3 2025, compared to $21.3 million in Q2 2025 and $24.2 million in Q1 2025.